Top ▲

ABL proto-oncogene 1, non-receptor tyrosine kinase

Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 1923

Nomenclature: ABL proto-oncogene 1, non-receptor tyrosine kinase

Abbreviated Name: Abl

Family: Abl family

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 1130 9q34.12 ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase
Mouse - 1123 2 B Abl1 c-abl oncogene 1, non-receptor tyrosine kinase
Rat - 1143 3p12 Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase
Previous and Unofficial Names Click here for help
Ab | Abelson murine leukemia viral (v-abl) oncogene homolog 1 | JTK7 | tyrosine-protein kinase ABL1 | ABL proto-oncogene 1
Database Links Click here for help
BRENDA
CATH/Gene3D
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
KEGG Gene
OMIM
Orphanet
Pharos
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  CRYSTAL STRUCTURE OF THE ABL-SH3 DOMAIN COMPLEXED WITH A DESIGNED HIGH-AFFINITY PEPTIDE LIGAND: IMPLICATIONS FOR SH3-LIGAND INTERACTIONS
PDB Id:  1BBZ
Resolution:  1.65Å
Species:  Human
References:  23
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of the c-Abl kinase domain in complex with INNO-406
PDB Id:  2E2B
Ligand:  bafetinib
Resolution:  2.2Å
Species:  Human
References:  14
Image of receptor 3D structure from RCSB PDB
Description:  The crystal structure of human abl1 kinase domain in complex with DCC-2036
PDB Id:  3QRI
Ligand:  rebastinib
Resolution:  2.1Å
Species:  Human
References:  5
Enzyme Reaction Click here for help
EC Number: 2.7.10.2

Download all structure-activity data for this target as a CSV file go icon to follow link

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
dasatinib Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 10.5 pKd 33
pKd 10.5 (Kd 3.2x10-11 M) [33]
Description: Binding affinity for the unphosphorylated kinase domain of the human ABL protein.
olverembatinib Small molecule or natural product Immunopharmacology Ligand Hs Inhibition 9.5 pKd 25
pKd 9.5 (Kd 3.2x10-10 M) [25]
Description: Binding affinity for nonphosphorylated Abl1 as determined using an active-site-dependent competitive binding assay (KINOMEscan).
SIAIS178 Small molecule or natural product Immunopharmacology Ligand Hs Inhibition 9.5 pKd 33
pKd 9.5 (Kd 3.5x10-10 M) [33]
Description: Binding affinity for the unphosphorylated kinase domain of the human ABL protein.
PD-173955 Small molecule or natural product Primary target of this compound Ligand has a PDB structure Hs Inhibition 9.2 pKd 7
pKd 9.2 (Kd 5.8x10-10 M) [7]
ZAK inhibitor 6p Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.8 pKd 31
pKd 7.8 (Kd 1.5x10-8 M) [31]
BO1 Small molecule or natural product Hs Inhibition 7.0 – 7.4 pKi 6,24
pKi 7.0 – 7.4 (Ki 1x10-7 – 4.4x10-8 M) [6,24]
compound 8h [PMID: 21561767] Small molecule or natural product Primary target of this compound Click here for species-specific activity table Hs Inhibition 9.7 pIC50 27
pIC50 9.7 (IC50 2x10-10 M) [27]
dasatinib Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 9.6 pIC50 17
pIC50 9.6 (IC50 2.7x10-10 M) [17]
olverembatinib Small molecule or natural product Immunopharmacology Ligand Hs Inhibition 9.5 pIC50 25
pIC50 9.5 (IC50 3.4x10-10 M) [25]
Description: Inhibition of wild type Abl1 kinase activity was determined using the proprietary FRET-based Z′-Lyte assay.
PF-114 Small molecule or natural product Hs Inhibition 9.3 pIC50 19
pIC50 9.3 (IC50 4.9x10-10 M) [19]
Description: Inhibition of native ABL kinase activity.
compound 24 [PMID: 23441572] Small molecule or natural product Primary target of this compound Click here for species-specific activity table Hs Inhibition 9.3 pIC50 8
pIC50 9.3 (IC50 5x10-10 M) [8]
rebastinib Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 9.1 pIC50 5,22
pIC50 9.1 (IC50 8x10-10 M) [5,22]
bosutinib Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 9.0 pIC50 12
pIC50 9.0 (IC50 1x10-9 M) [12]
compound 2c [PMID: 24900538] Small molecule or natural product Click here for species-specific activity table Hs Inhibition 8.9 pIC50 28
pIC50 8.9 (IC50 1.2x10-9 M) [28]
flumatinib Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 8.9 pIC50 18
pIC50 8.9 (IC50 1.2x10-9 M) [18]
pexmetinib Small molecule or natural product Click here for species-specific activity table Hs Inhibition 8.4 pIC50 4
pIC50 8.4 (IC50 4x10-9 M) [4]
ZAK inhibitor 6p Small molecule or natural product Click here for species-specific activity table Hs Inhibition 8.4 pIC50 31
pIC50 8.4 (IC50 4x10-9 M) [31]
Description: Inhibition of enzymatic activity determined in a ADP-GloTM assay.
PD-173955 Small molecule or natural product Primary target of this compound Ligand has a PDB structure Hs Inhibition ~8.3 pIC50 20
pIC50 ~8.3 (IC50 ~5x10-9 M) [20]
ponatinib Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 8.1 pIC50 15
pIC50 8.1 (IC50 8.6x10-9 M) [15]
bafetinib Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 7.6 – 8.2 pIC50 14,16
pIC50 7.6 – 8.2 (IC50 2.6x10-8 – 5.8x10-9 M) [14,16]
KW-2449 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 7.8 pIC50 26
pIC50 7.8 (IC50 1.4x10-8 M) [26]
nilotinib Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.8 pIC50 21
pIC50 7.8 (IC50 1.5x10-8 M) [21]
PP121 Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.7 pIC50 3
pIC50 7.7 (IC50 1.8x10-8 M) [3]
saracatinib Small molecule or natural product Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.5 pIC50 13
pIC50 7.5 (IC50 3x10-8 M) [13]
vodobatinib Small molecule or natural product Hs Inhibition 6.8 – 8.2 pIC50 2
pIC50 8.2 (IC50 6x10-9 M) [2]
Description: Inhibition of Abl1F311L expressed in in Ba/F3 cells.
pIC50 8.1 (IC50 7x10-9 M) [2]
Description: Inhibition of wild type Abl1 expressed in in Ba/F3 cells.
pIC50 6.8 (IC50 1.65x10-7 M) [2]
Description: Inhibition of Abl1E255V expressed in in Ba/F3 cells.
imatinib Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 6.7 pIC50 14
pIC50 6.7 (IC50 2.2x10-7 M) [14]
GNF-5 Small molecule or natural product Primary target of this compound Hs Inhibition 6.7 pIC50 32
pIC50 6.7 (IC50 2.2x10-7 M) [32]
Description: Inhibition of wild-type Abl in vitro.
eCF506 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 6.3 pIC50 10
pIC50 6.3 (IC50 4.79x10-7 M) [10]
DDR1/2 inhibitor 5n Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 6.3 pIC50 29
pIC50 6.3 (IC50 4.94x10-7 M) [29]
Inhibitor Comments
Note that bosutinib has inhibitory activity at other kinases including HCK, LYN and Src.
KW-2449 inhibits Abl1T315I with IC50 of 4nM [26].
Compound 24 [PMID 23441572] inhibits Abl1T315I, Abl1H396P, Abl1Q252H, Abl1M351T and Abl1Y253F with IC50 values between 0.3-0.5nM [8].
Compound 8h [PMID 21561767] inhibits Abl1T315I with IC50 of 0.4nM [27].
Allosteric Modulators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
asciminib Small molecule or natural product Ligand has a PDB structure Hs Negative 8.6 – 9.5 pIC50 9
pIC50 8.6 – 9.5 (IC50 2.4x10-9 – 3x10-10 M) [9]
Description: Two assays used: a radiometric filter-binding assay and microfluidic mobility shift technology (Caliper assay).
DiscoveRx KINOMEscan® screen Click here for help
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan
Reference: 7,30

Key to terms and symbols Click column headers to sort
Target used in screen: ABL1(E255K)-phosphorylated
Ligand Sp. Type Action Value Parameter
bosutinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.3 pKd
dasatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.3 pKd
PD-173955 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 9.3 pKd
tozasertib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.5 pKd
vandetanib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.9 pKd
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.7 pKd
canertinib Small molecule or natural product Immunopharmacology Ligand Hs Inhibitor Inhibition 7.5 pKd
nilotinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.4 pKd
KW-2449 Small molecule or natural product Hs Inhibitor Inhibition 7.4 pKd
fedratinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.4 pKd
Target used in screen: ABL1(F317I)-nonphosphorylated
Ligand Sp. Type Action Value Parameter
dasatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.0 pKd
bosutinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 9.2 pKd
AST-487 Small molecule or natural product Hs Inhibitor Inhibition 8.7 pKd
PD-173955 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.3 pKd
masitinib Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 8.1 pKd
imatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 8.1 pKd
nilotinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.7 pKd
foretinib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.4 pKd
NVP-TAE684 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.0 pKd
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 6.3 pKd
Target used in screen: ABL1(F317I)-phosphorylated
Ligand Sp. Type Action Value Parameter
dasatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.4 pKd
bosutinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 9.7 pKd
PD-173955 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.3 pKd
AST-487 Small molecule or natural product Hs Inhibitor Inhibition 7.9 pKd
NVP-TAE684 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.8 pKd
nilotinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.3 pKd
masitinib Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 7.1 pKd
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 6.9 pKd
vandetanib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 6.8 pKd
foretinib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 6.6 pKd
Target used in screen: ABL1(F317L)-nonphosphorylated
Ligand Sp. Type Action Value Parameter
dasatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.5 pKd
bosutinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.0 pKd
AST-487 Small molecule or natural product Hs Inhibitor Inhibition 9.1 pKd
imatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 8.6 pKd
PD-173955 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.5 pKd
masitinib Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 8.0 pKd
nilotinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.9 pKd
foretinib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.7 pKd
NVP-TAE684 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.3 pKd
vandetanib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.1 pKd
Target used in screen: ABL1(F317L)-phosphorylated
Ligand Sp. Type Action Value Parameter
dasatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.7 pKd
bosutinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.5 pKd
PD-173955 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.6 pKd
AST-487 Small molecule or natural product Hs Inhibitor Inhibition 7.9 pKd
nilotinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.8 pKd
NVP-TAE684 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.7 pKd
vandetanib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.5 pKd
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.3 pKd
canertinib Small molecule or natural product Immunopharmacology Ligand Hs Inhibitor Inhibition 7.0 pKd
KW-2449 Small molecule or natural product Hs Inhibitor Inhibition 7.0 pKd
Target used in screen: ABL1(H396P)-nonphosphorylated
Ligand Sp. Type Action Value Parameter
dasatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.6 pKd
bosutinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.2 pKd
PD-173955 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 9.2 pKd
AST-487 Small molecule or natural product Hs Inhibitor Inhibition 8.6 pKd
tozasertib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.5 pKd
nilotinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 8.3 pKd
imatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 8.2 pKd
vandetanib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 8.0 pKd
foretinib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.0 pKd
masitinib Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 8.0 pKd
Target used in screen: ABL1(H396P)-phosphorylated
Ligand Sp. Type Action Value Parameter
dasatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.3 pKd
bosutinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.2 pKd
PD-173955 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.9 pKd
tozasertib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.5 pKd
vandetanib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.8 pKd
nilotinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.7 pKd
axitinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.6 pKd
KW-2449 Small molecule or natural product Hs Inhibitor Inhibition 7.6 pKd
AST-487 Small molecule or natural product Hs Inhibitor Inhibition 7.5 pKd
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.4 pKd
Target used in screen: ABL1(M351T)-phosphorylated
Ligand Sp. Type Action Value Parameter
dasatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.8 pKd
bosutinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.4 pKd
PD-173955 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 9.3 pKd
tozasertib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.3 pKd
nilotinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.8 pKd
vandetanib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.8 pKd
KW-2449 Small molecule or natural product Hs Inhibitor Inhibition 7.7 pKd
AST-487 Small molecule or natural product Hs Inhibitor Inhibition 7.5 pKd
foretinib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.4 pKd
axitinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.4 pKd
Target used in screen: ABL1(Q252H)-nonphosphorylated
Ligand Sp. Type Action Value Parameter
dasatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.4 pKd
bosutinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.1 pKd
AST-487 Small molecule or natural product Hs Inhibitor Inhibition 9.0 pKd
PD-173955 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.9 pKd
imatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 8.7 pKd
tozasertib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.4 pKd
foretinib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.4 pKd
masitinib Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 8.2 pKd
nilotinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 8.0 pKd
vandetanib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.7 pKd
Target used in screen: ABL1(Q252H)-phosphorylated
Ligand Sp. Type Action Value Parameter
bosutinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.4 pKd
dasatinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 10.2 pKd
PD-173955 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 9.0 pKd
masitinib Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 8.3 pKd
tozasertib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.0 pKd
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.0 pKd
vandetanib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.8 pKd
nilotinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.7 pKd
KW-2449 Small molecule or natural product Hs Inhibitor Inhibition 7.7 pKd
canertinib Small molecule or natural product Immunopharmacology Ligand Hs Inhibitor Inhibition 7.7 pKd
Target used in screen: ABL1(T315I)-nonphosphorylated
Ligand Sp. Type Action Value Parameter
AST-487 Small molecule or natural product Hs Inhibitor Inhibition 8.6 pKd
axitinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 8.4 pKd
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.1 pKd
tozasertib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.0 pKd
crizotinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 7.9 pKd
KW-2449 Small molecule or natural product Hs Inhibitor Inhibition 7.9 pKd
foretinib Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.7 pKd
bosutinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 7.7 pKd
NVP-TAE684 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 7.3 pKd
doramapimod Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 7.2 pKd
Target used in screen: ABL1(T315I)-phosphorylated
Ligand Sp. Type Action Value Parameter
axitinib Small molecule or natural product Approved drug Ligand has a PDB structure Hs Inhibitor Inhibition 8.8 pKd
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 8.5 pKd
bosutinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 8.4 pKd
NVP-TAE684 Small molecule or natural product Ligand has a PDB structure